Adenosine receptor activation ameliorates type 1 diabetes

Zoltán H. Németh, David Bleich, Balázs Csóka, Pál Pacher, Jon G. Mabley, Leonóra Himer, E. Sylvester Vizi, Edwin A. Deitch, Csaba Szabo, Bruce N. Cronstein, György Haskó

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Growing evidence indicates that adenosine receptors could be promising therapeutic targets in autoimmune diseases. Here we studied the role of adenosine receptors in controlling the course of type 1 diabetes. Diabetes in CD-1 mice was induced by multiple-low-dose-streptozotocin (MLDS) treatment and in nonobese diabetic (NOD) mice by cyclophosphamide injection. The nonselective adenosine receptor agonist 5′-N-ethylcarboxamidoadenosine (NECA) prevented diabetes development in both MLDS-challenged mice and in cyclophosphamide- treated NOD mice. The effect of NECA was reversed by the selective A 2B receptor antagonist N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2, 6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]acetamide (MRS 1754). The selective A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) and A3 receptor agonist N6-(3-iodobenzyl)- adenosine-5′-N-methyluronamide (IB-MECA) were less efficacious in ameliorating the course of diabetes. NECA inhibited diabetes in A2A receptor KO mice and the selective A2A receptor agonist 2-p-(2-carboxyethyl)phenethyl-amino-5′-N-ethyl-carboxamidoadenosine (CGS21680) had no effect in normal mice, indicating a lack of role of A 2A receptors. NECA failed to prevent cytokine-induced β-cell death in vitro, but NECA strongly suppressed expression of the proinflammatory cytokines TNF-α, MIP-1α, IL-12, and IFN-γ in pancreata, endotoxin, or anti-CD3-stimulated splenic cells, and T helper 1 lymphocytes, indicating that the beneficial effect of NECA was due to immunomodulation. These results demonstrate that adenosine receptor ligands are potential candidates for the treatment of type 1 diabetes.

Original languageEnglish (US)
Pages (from-to)2379-2388
Number of pages10
JournalFASEB Journal
Volume21
Issue number10
DOIs
StatePublished - Aug 2007
Externally publishedYes

Fingerprint

Adenosine-5'-(N-ethylcarboxamide)
Purinergic P1 Receptors
insulin-dependent diabetes mellitus
adenosine
Medical problems
Type 1 Diabetes Mellitus
Chemical activation
receptors
Inbred NOD Mouse
agonists
diabetes
Streptozocin
mice
Cyclophosphamide
cyclophosphamide
Purinergic P1 Receptor Agonists
Cytokines
streptozotocin
Immunomodulation
Lymphocytes

Keywords

  • Immune
  • Inflammation
  • Islet

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Németh, Z. H., Bleich, D., Csóka, B., Pacher, P., Mabley, J. G., Himer, L., ... Haskó, G. (2007). Adenosine receptor activation ameliorates type 1 diabetes. FASEB Journal, 21(10), 2379-2388. https://doi.org/10.1096/fj.07-8213com

Adenosine receptor activation ameliorates type 1 diabetes. / Németh, Zoltán H.; Bleich, David; Csóka, Balázs; Pacher, Pál; Mabley, Jon G.; Himer, Leonóra; Vizi, E. Sylvester; Deitch, Edwin A.; Szabo, Csaba; Cronstein, Bruce N.; Haskó, György.

In: FASEB Journal, Vol. 21, No. 10, 08.2007, p. 2379-2388.

Research output: Contribution to journalArticle

Németh, ZH, Bleich, D, Csóka, B, Pacher, P, Mabley, JG, Himer, L, Vizi, ES, Deitch, EA, Szabo, C, Cronstein, BN & Haskó, G 2007, 'Adenosine receptor activation ameliorates type 1 diabetes', FASEB Journal, vol. 21, no. 10, pp. 2379-2388. https://doi.org/10.1096/fj.07-8213com
Németh ZH, Bleich D, Csóka B, Pacher P, Mabley JG, Himer L et al. Adenosine receptor activation ameliorates type 1 diabetes. FASEB Journal. 2007 Aug;21(10):2379-2388. https://doi.org/10.1096/fj.07-8213com
Németh, Zoltán H. ; Bleich, David ; Csóka, Balázs ; Pacher, Pál ; Mabley, Jon G. ; Himer, Leonóra ; Vizi, E. Sylvester ; Deitch, Edwin A. ; Szabo, Csaba ; Cronstein, Bruce N. ; Haskó, György. / Adenosine receptor activation ameliorates type 1 diabetes. In: FASEB Journal. 2007 ; Vol. 21, No. 10. pp. 2379-2388.
@article{8eec9f927b4c4d2fa9f720343861b13d,
title = "Adenosine receptor activation ameliorates type 1 diabetes",
abstract = "Growing evidence indicates that adenosine receptors could be promising therapeutic targets in autoimmune diseases. Here we studied the role of adenosine receptors in controlling the course of type 1 diabetes. Diabetes in CD-1 mice was induced by multiple-low-dose-streptozotocin (MLDS) treatment and in nonobese diabetic (NOD) mice by cyclophosphamide injection. The nonselective adenosine receptor agonist 5′-N-ethylcarboxamidoadenosine (NECA) prevented diabetes development in both MLDS-challenged mice and in cyclophosphamide- treated NOD mice. The effect of NECA was reversed by the selective A 2B receptor antagonist N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2, 6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]acetamide (MRS 1754). The selective A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) and A3 receptor agonist N6-(3-iodobenzyl)- adenosine-5′-N-methyluronamide (IB-MECA) were less efficacious in ameliorating the course of diabetes. NECA inhibited diabetes in A2A receptor KO mice and the selective A2A receptor agonist 2-p-(2-carboxyethyl)phenethyl-amino-5′-N-ethyl-carboxamidoadenosine (CGS21680) had no effect in normal mice, indicating a lack of role of A 2A receptors. NECA failed to prevent cytokine-induced β-cell death in vitro, but NECA strongly suppressed expression of the proinflammatory cytokines TNF-α, MIP-1α, IL-12, and IFN-γ in pancreata, endotoxin, or anti-CD3-stimulated splenic cells, and T helper 1 lymphocytes, indicating that the beneficial effect of NECA was due to immunomodulation. These results demonstrate that adenosine receptor ligands are potential candidates for the treatment of type 1 diabetes.",
keywords = "Immune, Inflammation, Islet",
author = "N{\'e}meth, {Zolt{\'a}n H.} and David Bleich and Bal{\'a}zs Cs{\'o}ka and P{\'a}l Pacher and Mabley, {Jon G.} and Leon{\'o}ra Himer and Vizi, {E. Sylvester} and Deitch, {Edwin A.} and Csaba Szabo and Cronstein, {Bruce N.} and Gy{\"o}rgy Hask{\'o}",
year = "2007",
month = "8",
doi = "10.1096/fj.07-8213com",
language = "English (US)",
volume = "21",
pages = "2379--2388",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "10",

}

TY - JOUR

T1 - Adenosine receptor activation ameliorates type 1 diabetes

AU - Németh, Zoltán H.

AU - Bleich, David

AU - Csóka, Balázs

AU - Pacher, Pál

AU - Mabley, Jon G.

AU - Himer, Leonóra

AU - Vizi, E. Sylvester

AU - Deitch, Edwin A.

AU - Szabo, Csaba

AU - Cronstein, Bruce N.

AU - Haskó, György

PY - 2007/8

Y1 - 2007/8

N2 - Growing evidence indicates that adenosine receptors could be promising therapeutic targets in autoimmune diseases. Here we studied the role of adenosine receptors in controlling the course of type 1 diabetes. Diabetes in CD-1 mice was induced by multiple-low-dose-streptozotocin (MLDS) treatment and in nonobese diabetic (NOD) mice by cyclophosphamide injection. The nonselective adenosine receptor agonist 5′-N-ethylcarboxamidoadenosine (NECA) prevented diabetes development in both MLDS-challenged mice and in cyclophosphamide- treated NOD mice. The effect of NECA was reversed by the selective A 2B receptor antagonist N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2, 6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]acetamide (MRS 1754). The selective A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) and A3 receptor agonist N6-(3-iodobenzyl)- adenosine-5′-N-methyluronamide (IB-MECA) were less efficacious in ameliorating the course of diabetes. NECA inhibited diabetes in A2A receptor KO mice and the selective A2A receptor agonist 2-p-(2-carboxyethyl)phenethyl-amino-5′-N-ethyl-carboxamidoadenosine (CGS21680) had no effect in normal mice, indicating a lack of role of A 2A receptors. NECA failed to prevent cytokine-induced β-cell death in vitro, but NECA strongly suppressed expression of the proinflammatory cytokines TNF-α, MIP-1α, IL-12, and IFN-γ in pancreata, endotoxin, or anti-CD3-stimulated splenic cells, and T helper 1 lymphocytes, indicating that the beneficial effect of NECA was due to immunomodulation. These results demonstrate that adenosine receptor ligands are potential candidates for the treatment of type 1 diabetes.

AB - Growing evidence indicates that adenosine receptors could be promising therapeutic targets in autoimmune diseases. Here we studied the role of adenosine receptors in controlling the course of type 1 diabetes. Diabetes in CD-1 mice was induced by multiple-low-dose-streptozotocin (MLDS) treatment and in nonobese diabetic (NOD) mice by cyclophosphamide injection. The nonselective adenosine receptor agonist 5′-N-ethylcarboxamidoadenosine (NECA) prevented diabetes development in both MLDS-challenged mice and in cyclophosphamide- treated NOD mice. The effect of NECA was reversed by the selective A 2B receptor antagonist N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2, 6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]acetamide (MRS 1754). The selective A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) and A3 receptor agonist N6-(3-iodobenzyl)- adenosine-5′-N-methyluronamide (IB-MECA) were less efficacious in ameliorating the course of diabetes. NECA inhibited diabetes in A2A receptor KO mice and the selective A2A receptor agonist 2-p-(2-carboxyethyl)phenethyl-amino-5′-N-ethyl-carboxamidoadenosine (CGS21680) had no effect in normal mice, indicating a lack of role of A 2A receptors. NECA failed to prevent cytokine-induced β-cell death in vitro, but NECA strongly suppressed expression of the proinflammatory cytokines TNF-α, MIP-1α, IL-12, and IFN-γ in pancreata, endotoxin, or anti-CD3-stimulated splenic cells, and T helper 1 lymphocytes, indicating that the beneficial effect of NECA was due to immunomodulation. These results demonstrate that adenosine receptor ligands are potential candidates for the treatment of type 1 diabetes.

KW - Immune

KW - Inflammation

KW - Islet

UR - http://www.scopus.com/inward/record.url?scp=34547773217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547773217&partnerID=8YFLogxK

U2 - 10.1096/fj.07-8213com

DO - 10.1096/fj.07-8213com

M3 - Article

C2 - 17405852

AN - SCOPUS:34547773217

VL - 21

SP - 2379

EP - 2388

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 10

ER -